Phaseline

Targets › DSG3

DSG3 (Desmoglein-3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jan 2029.

A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. Required for adherens and desmosome junction assembly in response to mechanical force in keratinocytes. (UniProt, P32926)

Open in Phaseline: the race on DSG3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cabaletta BioDSG3-CAART
Desmoglein 3 chimeric autoantibody receptor T cells
DSG3Phase 1Pemphigus VulgarisJan 2029

Conditions

Pemphigus Vulgaris (1)

Modalities

protein or peptide (1)

Companies

Cabaletta Bio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.